SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Mometasone Dry Powder Inhaler Formulation

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
   Trade name : Mometasone Dry Powder Inhaler Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
   Use of the Substance/Mixture : Pharmaceutical

1.3 Details of the supplier of the safety data sheet
   Company : Organon & Co.
              30 Hudson Street, 33rd floor
              07302 Jersey City, New Jersey, U.S.A
   Telephone : 551-430-6000
   E-mail address of person responsible for the SDS : EHSSTEWARD@organon.com

1.4 Emergency telephone number
   215-631-6999

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
   Classification (REGULATION (EC) No 1272/2008)
   - Reproductive toxicity, Category 1B : H360Df: May damage the unborn child. Suspected of damaging fertility.
   - Specific target organ toxicity - repeated exposure, Category 2 : H373: May cause damage to organs through prolonged or repeated exposure.
   - Long-term (chronic) aquatic hazard, Category 1 : H410: Very toxic to aquatic life with long lasting effects.

2.2 Label elements
   Labelling (REGULATION (EC) No 1272/2008)
   Hazard pictograms : 
   Signal word : Danger
   Hazard statements : H360Df May damage the unborn child. Suspected of damaging fertility.
                      H373 May cause damage to organs through prolonged or repeated exposure.
                      H410 Very toxic to aquatic life with long lasting effects.
Precautionary statements:

**Prevention:**
- P201 Obtain special instructions before use.
- P260 Do not breathe dust.
- P273 Avoid release to the environment.
- P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**
- P308 + P313 IF exposed or concerned: Get medical advice/ attention.
- P391 Collect spillage.

**Hazardous components which must be listed on the label:**
Mometasone

**2.3 Other hazards**

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

**SECTION 3: Composition/information on ingredients**

**3.2 Mixtures**

**Components**

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No. EC-No. Index-No. Registration number</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mometasone</td>
<td>83919-23-7</td>
<td>Repr. 1B: H360Df STOT RE 2; H373 (Immune system, Liver, Kidney, Skin) Aquatic Chronic 1; H410</td>
<td>&gt;= 10 - &lt; 20</td>
</tr>
</tbody>
</table>

M-Factor (Chronic aquatic toxicity): 100

For explanation of abbreviations see section 16.
SECTION 4: First aid measures

4.1 Description of first aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled: If inhaled, remove to fresh air. Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks: May damage the unborn child. Suspected of damaging fertility. May cause damage to organs through prolonged or repeated exposure.

Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment: Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Mometasone Dry Powder Inhaler Formulation

Version 2.5  Revision Date: 09.04.2021  SDS Number: 493906-00013  Date of last issue: 10.10.2020  Date of first issue: 28.01.2016

5.2 Special hazards arising from the substance or mixture
Specific hazards during firefighting: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides
Chlorine compounds

5.3 Advice for firefighters
Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Specific extinguishing methods:
- Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Use water spray to cool unopened containers.
- Remove undamaged containers from fire area if it is safe to do so.
- Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures
Personal precautions: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions
Environmental precautions: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up
Methods for cleaning up: Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-
mine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections
See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures
Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation
If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling
Do not get on skin or clothing.
Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures
If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers
Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Advice on common storage
Do not store with the following product types:
Strong oxidizing agents
Organic peroxides
Explosives
Gases

7.3 Specific end use(s)
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Mometasone Dry Powder Inhaler Formulation

Version 2.5 Revision Date: 09.04.2021 SDS Number: 493906-00013 Date of last issue: 10.10.2020 Date of first issue: 28.01.2016

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mometasone</td>
<td>83919-23-7</td>
<td>TWA</td>
<td>1 µg/m³ (OEB 4)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Further information: Skin</td>
<td>Wipe limit</td>
<td>10 µg/100 cm²</td>
</tr>
</tbody>
</table>

8.2 Exposure controls

Engineering measures

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.). All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Essentially no open handling permitted. Use closed processing systems or containment technologies.

Personal protective equipment

Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 143

Filter type : Particulates type (P)
SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state: powder
Colour: white
Odour: No data available
Odour Threshold: No data available
Melting point/freezing point: No data available
Initial boiling point and boiling range: No data available
Flammability (solid, gas): May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids): No data available
Upper explosion limit / Upper flammability limit: No data available
Lower explosion limit / Lower flammability limit: No data available
Flash point: Not applicable
Auto-ignition temperature: No data available
Decomposition temperature
Decomposition temperature: No data available
pH: No data available
Viscosity
Viscosity, kinematic: No data available
Solubility(ies)
Water solubility: No data available
Partition coefficient: n-octanol/water: No data available
Vapour pressure: No data available
Relative density: No data available
Density: No data available
Relative vapour density: No data available
Particle characteristics
Particle size: No data available

9.2 Other information
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Mometasone Dry Powder Inhaler Formulation

Explosives : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.
Evaporation rate : No data available
Molecular weight : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions : May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid : Heat, flames and sparks. Avoid dust formation.

10.5 Incompatible materials
Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008
Information on likely routes of exposure : Inhalation
                                    Skin contact
                                    Ingestion
                                    Eye contact

Acute toxicity
Not classified based on available information.

Components:

Mometasone:
Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
                       LD50 (Mouse): > 2,000 mg/kg
Acute inhalation toxicity : LC50 (Rat): > 3.3 mg/l
                           Exposure time: 4 h
Test atmosphere: dust/mist
Remarks: No mortality observed at this dose.

LC50 (Mouse): > 3.2 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute toxicity (other routes of administration): LD50 (Rat): 300 mg/kg
Application Route: Subcutaneous
Symptoms: Breathing difficulties

Skin corrosion/irritation
Not classified based on available information.

Components:
Mometasone:
Species: Rabbit
Result: No skin irritation

Serious eye damage/eye irritation
Not classified based on available information.

Components:
Mometasone:
Species: Rabbit
Result: No eye irritation

Respiratory or skin sensitisation
Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:
Mometasone:
Test Type: Maximisation Test
Exposure routes: Dermal
Species: Guinea pig
Assessment: Does not cause skin sensitisation.
Result: negative
Remarks: The results of a test on guinea pigs showed this substance to be a weak skin sensitiser.

Germ cell mutagenicity
Not classified based on available information.
Components:

Mometasone:

Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  Result: negative
- Test Type: Chromosomal aberration
  Test system: Chinese hamster lung cells
  Result: negative
- Test Type: Chromosomal aberration
  Test system: Chinese hamster ovary cells
  Result: positive
- Test Type: Mouse Lymphoma
  Result: negative

Genotoxicity in vivo:
- Test Type: Micronucleus test
  Species: Mouse
  Application Route: Oral
  Result: negative
- Test Type: Chromosomal aberration
  Species: Rat
  Cell type: Bone marrow
  Result: negative
- Test Type: unscheduled DNA synthesis assay
  Species: Rat
  Cell type: Liver cells
  Result: negative

Germ cell mutagenicity - Assessment:
Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity:
Not classified based on available information.

Components:

Mometasone:

Species: Rat
Application Route: Inhalation
Exposure time: 2 Years
Dose: 0.067 mg/kg body weight
Result: negative

Species: Mouse
Application Route: Inhalation
Exposure time: 19 Months
Dose: 0.160 mg/kg body weight
Result: negative
Reproductive toxicity
May damage the unborn child. Suspected of damaging fertility.

Components:

Mometasone:
Effects on fertility:
- Test Type: Fertility
  - Species: Rat
  - Application Route: Subcutaneous
  - Fertility: NOAEL: 0.015 mg/kg body weight
  - Symptoms: Reduced embryonic survival, Reduced foetal weight
  - Result: No effects on fertility, Effect on reproduction capacity

Effects on foetal development:
- Test Type: Embryo-foetal development
  - Species: Mouse
  - Application Route: Subcutaneous
  - Embryo-foetal toxicity: LOAEL: 0.06 mg/kg body weight
  - Result: Embryotoxic effects, Teratogenicity and developmental toxicity

- Test Type: Embryo-foetal development
  - Species: Rat
  - Application Route: Dermal
  - Embryo-foetal toxicity: LOAEL: 0.3 mg/kg body weight
  - Result: Embryo-foetal toxicity

- Test Type: Embryo-foetal development
  - Species: Rabbit
  - Application Route: Dermal
  - Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight
  - Result: Embryo-foetal toxicity, Malformations were observed.

- Test Type: Embryo-foetal development
  - Species: Rat
  - Application Route: Subcutaneous
  - Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight
  - Result: Effects on newborn

- Test Type: Embryo-foetal development
  - Species: Rabbit
  - Application Route: Oral
  - Embryo-foetal toxicity: LOAEL: 0.7 mg/kg body weight
  - Result: Embryo-foetal toxicity, Malformations were observed.

Reproductive toxicity - Assessment:
- Clear evidence of adverse effects on development, based on animal experiments.
- Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

STOT - single exposure
Not classified based on available information.
Components:
Mometasone:
Remarks: Based on available data, the classification criteria are not met.

STOT - repeated exposure
May cause damage to organs through prolonged or repeated exposure.

Components:
Mometasone:
Exposure routes: inhalation (dust/mist/fume)
Target Organs: Immune system, Liver, Kidney, Skin
Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:
Mometasone:
Species: Rat
NOAEL: 0.005 mg/kg
LOAEL: 0.3 mg/kg
Application Route: Oral
Exposure time: 30 d
Target Organs: Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species: Dog
NOAEL: 0.5 mg/kg
Application Route: Oral
Exposure time: 30 d
Target Organs: Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species: Rat
NOAEL: 0.00013 mg/l
Application Route: inhalation (dust/mist/fume)
Exposure time: 90 d
Target Organs: Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, Liver, thymus gland

Species: Dog
NOAEL: 0.0005 mg/l
Application Route: inhalation (dust/mist/fume)
Exposure time: 90 d
Target Organs: Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, thymus gland, Liver

Aspiration toxicity
Not classified based on available information.
Components:

Mometasone:
Not applicable

11.2 Information on other hazards

Endocrine disrupting properties

Product:
Assessment: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:

Mometasone:
Inhalation: Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion
Skin contact: Symptoms: Dermatitis, Itching

Further information

Components:

Mometasone:
Remarks: Dermal absorption possible

SECTION 12: Ecological information

12.1 Toxicity

Components:

Mometasone:
Toxicity to fish
LC50 (Menidia beryllina (Silverside)): 0.11 mg/l
Exposure time: 96 h
Remarks: No toxicity at the limit of solubility

LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l
Exposure time: 7 d
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates
EC50 (Daphnia magna (Water flea)): > 5 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility
EC50 (Americamysis): > 5 mg/l
Exposure time: 96 h
Method: US-EPA OPPTS 850.1035
Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic plants: EC50 (Pseudokirchneriella subcapitata (green algae)): > 3.2 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms: EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility

NOEC: 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic toxicity): NOEC: 0.00014 mg/l
Exposure time: 32 d
Species: Pimephales promelas (fathead minnow)
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity): NOEC: 0.34 mg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
Method: OECD Test Guideline 211
Remarks: No toxicity at the limit of solubility

M-Factor (Chronic aquatic toxicity): 100

12.2 Persistence and degradability

Components:

Mometasone:
Biodegradability: Result: Not readily biodegradable.
Biodegradation: 50 %
Exposure time: 28 d
Method: OECD Test Guideline 314

Stability in water: Hydrolysis: 50 % (12 d)
Method: OECD Test Guideline 111

12.3 Bioaccumulative potential

Components:

Mometasone:
Bioaccumulation: Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 107.1
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water: log Pow: 4.68

12.4 Mobility in soil

Components:

Mometasone:
Distribution among environmental compartments: log Koc: 4.02

12.5 Results of PBT and vPvB assessment

Product:
Assessment: This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties

Product:
Assessment: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN: UN 3077
Mometasone Dry Powder Inhaler Formulation

14.2 UN proper shipping name

| ADN            | ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone) |
| ADR            | ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone) |
| RID            | ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone) |
| IMDG           | ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone) |
| IATA           | Environmentally hazardous substance, solid, n.o.s. (Mometasone) |

14.3 Transport hazard class(es)

| ADN | 9 |
| ADR | 9 |
| RID | 9 |
| IMDG| 9 |
| IATA| 9 |

14.4 Packing group

| ADN   | Packing group: III Classification Code: M7 Hazard Identification Number: 90 Labels: 9 |
| ADR   | Packing group: III Classification Code: M7 Hazard Identification Number: 90 Labels: 9 Tunnel restriction code: (-) |
| RID   | Packing group: III Classification Code: M7 Hazard Identification Number: 90 Labels: 9 |
14.5 Environmental hazards

<table>
<thead>
<tr>
<th>ADN</th>
<th>Environmentally hazardous</th>
<th>yes</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADR</td>
<td>Environmentally hazardous</td>
<td>yes</td>
</tr>
<tr>
<td>RID</td>
<td>Environmentally hazardous</td>
<td>yes</td>
</tr>
<tr>
<td>IMDG</td>
<td>Marine pollutant</td>
<td>yes</td>
</tr>
<tr>
<td>IATA (Passenger)</td>
<td>Environmentally hazardous</td>
<td>yes</td>
</tr>
</tbody>
</table>

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments

| Remarks | Not applicable for product as supplied. |

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

| REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII) | Not applicable |
| REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59). | Not applicable |
Mometasone Dry Powder Inhaler Formulation

REACH - List of substances subject to authorisation (Annex XIV): Not applicable
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer: Not applicable
Regulation (EU) 2019/1021 on persistent organic pollutants (recast): Not applicable
Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals: Not applicable

Other regulations:
Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.
Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Full text of H-Statements
H360Df : May damage the unborn child. Suspected of damaging fertility.
H373 : May cause damage to organs through prolonged or repeated exposure if inhaled.
H410 : Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations
Aquatic Chronic : Long-term (chronic) aquatic hazard
Repr. : Reproductive toxicity
STOT RE : Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation;
Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information


Classification of the mixture:

<table>
<thead>
<tr>
<th>Repr. 1B</th>
<th>STOT RE 2</th>
<th>Aquatic Chronic 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>H360Df</td>
<td>H373</td>
<td>H410</td>
</tr>
</tbody>
</table>

Classification procedure:

Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

IE / EN